Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

AstraZeneca plc : AstraZeneca and Bristol-Myers Squibb resubmit dapagliflozin New Drug Application for the treatment of type 2 diabetes in the U.S

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/25/2013 | 02:26pm CEST

AstraZeneca and Bristol-Myers Squibb today announced they have resubmitted to the U.S. Food and Drug Administration (FDA), a New Drug Application (NDA) for dapagliflozin for the treatment of adults with type 2 diabetes.

The NDA resubmission, which is pending acceptance by the FDA, includes several new studies and additional long-term data (up to four years' duration) from previously submitted studies.

NOTES TO EDITORS About dapagliflozin

Dapagliflozin, an investigational compound, is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2), which works independently of insulin. It is currently approved for the treatment of type 2 diabetes in the European Union, Australia, Brazil, Mexico and New Zealand.

About Type 2 Diabetes

In 2012, diabetes was estimated to affect more than 370 million people worldwide. The prevalence of diabetes is projected to reach more than 550 million by 2030. Type 2 diabetes accounts for approximately 90 to 95% of all cases of diagnosed diabetes in adults. Type 2 diabetes is a chronic disease characterised by insulin resistance and dysfunction of beta cells in the pancreas, leading to elevated glucose levels. Over time, this sustained hyperglycemia contributes to further progression of the disease. Significant unmet needs still exist, as many patients remain inadequately controlled on their current glucose-lowering regimen.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.www.astrazeneca.com

CONTACTS Media Enquiries

Esra Erkal-Paler +44 20 7604 8030 (UK/Global)
Vanessa Rhodes +44 20 7604 8037 (UK/Global)
Ayesha Bharmal +44 20 7604 8034 (UK/Global)
Michele Meixell +1 302 885 2677 (US)
Jacob Lund +46 8 553 260 20 (Sweden)

Colleen Proctor + 44 207 604 8128 mob: +1 302 357 4882
Ed Seage + 44 207 604 8125 mob: +1 302 373 1361

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA PLC
05/26 ASTRAZENECA : Bydureon EXSCEL trial meets primary safety objective in type-2 dia..
05/26 ASTRAZENECA PLC (ADR)(NYSE : AZN)’s Bydureon Failed To Reach Statistical S..
05/26 ASTRAZENECA : Delivers New Data on Expanding Portfolio of Cancer Medicines at 20..
05/26 ASTRAZENECA : NCCN Awards Grants to Investigators at Member Institutions to Stud..
05/26 RECORDATI : Hogan Lovells Acts for Recordati on US$300 Million Acquisition of Co..
05/25 ASTRAZENECA : Initiates Voluntary Nationwide Recall of One Lot of BRILINTA 90mg ..
05/25 ASTRAZENECA : Brilique (ticagrelor) new formulation gains European approval
05/25 ASTRAZENECA : enters agreement with Recordati for Seloken in Europe
05/25 ASTRAZENECA : Francis Crick Institute signs new research agreement with AstraZen..
05/24 FTSE edges up helped by M&S, but miners weigh
More news
Sector news : Pharmaceuticals - NEC
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/26 AstraZeneca announces extensive lineup of abstracts at ASCO
05/26 AstraZeneca initiates nationwide voluntary recall of one lot of BRILINTA 90mg..
05/25 Is OncoMed A Contrarian Buy?
05/25 3 THINGS IN BIOTECH YOU SHOULD LEARN : May 25, 2017
05/25 FDA drug approvals rebound from last year, up over 100% yoy
Advertisement
Financials ($)
Sales 2017 21 491 M
EBIT 2017 5 791 M
Net income 2017 2 649 M
Debt 2017 12 465 M
Yield 2017 4,08%
P/E ratio 2017 30,99
P/E ratio 2018 24,64
EV / Sales 2017 4,56x
EV / Sales 2018 4,48x
Capitalization 85 598 M
More Financials
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 34
Average target price 66,1 $
Spread / Average Target -1,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC17.39%85 598
JOHNSON & JOHNSON10.69%341 901
ROCHE HOLDING LTD.14.88%236 581
NOVARTIS AG6.75%211 457
PFIZER INC.-1.05%191 398
MERCK & CO., INC.10.28%177 567
More Results